Promoting Competition
and Investment in the
U.S. Life Sciences Ecosystem
The U.S. life sciences ecosystem depends on mergers and acquisitions (M&A) to bring together the resources, investment and expertise needed to develop and deliver treatments and cures for patients.
FUELING COMPETITION AND INVESTMENT
M&A drives competition and investment across America's life sciences industry.
FACILITATING INNOVATION
Life sciences companies of all sizes engage in M&A to connect innovations with the resources needed to bring them to market.
DRIVING AMERICAN GROWTH, LEADERSHIP
M&A plays a critical role within America’s world-class life sciences industry.
biopharmaceutical companies headquartered in the U.S.
PARTNERS
ABOUT US
PULSE is a national coalition raising awareness about the unique and fundamental role of mergers and acquisitions (M&A) in America’s life sciences industry. M&A enables life sciences companies of all sizes to bring together resources, investment and expertise needed to develop and deliver new treatments and cures. PULSE members represent researchers, manufacturers and leaders of life sciences companies of all sizes that make up a diverse, vibrant life sciences industry across America.
LATEST NEWS
Q2 2026 Highlights – Partnership for the U.S. Life Science Ecosystem (PULSE)
PULSE and its network of nearly 40 partners have continued to build awareness of the unique and fundamental role of life sciences mergers and acquisitions (M&A) and other pro-competitive partnerships. Read below for a round-up of recent PULSE updates and...
States Must Preserve Balanced Approach to Life Sciences Antitrust Enforcement
Policymakers in California, New York and across the country are considering state-level antitrust proposals that could chill innovation, competition and growth in key industries, including life sciences.
PULSE Urges FTC, DOJ to Support Pro-Competitive Life Sciences Collaborations and M&A
In recent comments to the Department of Justice (DOJ) and Federal Trade Commission (FTC), PULSE highlighted critical reforms to ensure that U.S. competition policies support – and do not impede – the pro-competitive mergers and acquisitions (M&A) and other collaborations that drive American life sciences innovation.